Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Rivaroxaban cuts risk of repeat heart attack

  • Comment

Patients who take an oral anticlotting drug after a heart attack reduce their chances of suffering further complications, according to a study.

Researchers from the Brigham and Women’s Hospital in the US found that administering rivaroxaban to patients who had suffered an acute coronary syndrome - such as heart attack or unstable angina - cut the incidence of stroke, further heart attack and even death.

The study, published in the Lancet, showed that rivaroxaban inhibits a molecule involved in the blood clotting mechanism, known as factor Xa.

Previous research showed it to be effective in the prevention of venous thromboembolism in patients who had undergone orthopaedic surgery.

The researchers found that 5mg of rivaroxaban increased the chance of clinically significant bleeding by 2.2 times compared with placebo. This rose to five times for the 20mg dose.

Author Dr Jessica Mega said: ‘The use of an oral factor Xa inhibitor in patients stabilised after an acute coronary syndrome increases bleeding in a dose-dependent manner and might reduce major ischaemic outcomes.’

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs